Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow set for lower open after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Stock Movers 08/10: (HDSN) (GLPG) (PRGO) Higher; (BW) (QTM) (CBI) Lower (more...)
August 10, 2017 9:27 AM EDTToday's Pre-Open Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43... More
After-Hours Stock Movers 08/09: (HDSN) (ASYS) (LYV) Higher; (BW) (QTM) (CBI) Lower (more...)
August 9, 2017 6:01 PM EDTToday's After-Hours Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43 million.
Hudson... More
Anthera Pharma (ANTH) Confirms FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:01 PM EDTAnthera Pharmaceuticals (Nasdaq: ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
We are pleased by the FDAs decision to designate blisibimod with orphan drug designation, said Craig Thompson, Chief Executive Officer of... More
Anthera Pharma's (ANTH) Blisibimod Receives FDA Orphan Drug Status
August 9, 2017 6:25 AM EDTAnthera Pharma' (NASDAQ: ANTH) Blisibimod received FDA orphan drug status for treatment of patients with immunoglobulin A... More
